Innate immunity and immunotherapy for hemorrhagic shock

Abstract

Hemorrhagic shock (HS) is a shock result of hypovolemic injury, in which the innate immune response plays a central role in the pathophysiology ofthe severe complications and organ injury in surviving patients. During the development of HS, innate immunity acts as the first line of defense, mediating a rapid response to pathogens or danger signals through pattern recognition receptors. The early and exaggerated activation of innate immunity, which is widespread in patients with HS, results in systemic inflammation, cytokine storm, and excessive activation of complement factors and innate immune cells, comprised of type II innate lymphoid cells, CD4⁺ T cells, natural killer cells, eosinophils, basophils, macrophages, neutrophils, and dendritic cells. Recently, compelling evidence focusing on the innate immune regulation in preclinical and clinical studies promises new treatment avenues to reverse or minimize HS-induced tissue injury, organ dysfunction, and ultimately mortality. In this review, we first discuss the innate immune response involved in HS injury, and then systematically detail the cutting-edge therapeutic strategies in the past decade regarding the innate immune regulation in this field; these strategies include the use of mesenchymal stem cells, exosomes, genetic approaches, antibody therapy, small molecule inhibitors, natural medicine, mesenteric lymph drainage, vagus nerve stimulation, hormones, glycoproteins, and others. We also reviewed the available clinical studies on immune regulation for treating HS and assessed the potential of immune regulation concerning a translation from basic research to clinical practice. Combining therapeutic strategies with an improved understanding of how the innate immune system responds to HS could help to identify and develop targeted therapeutic modalities that mitigate severe organ dysfunction, improve patient outcomes, and reduce mortality due to HS injury.

Introduction

Hemorrhagic shock (HS) is a life-threatening condition occurring in various clinical situations, including trauma, childbirth, gastrointestinal hemorrhage, and aneurysmal rupture (1, 2). It is a represents a substantial global problem, which more than 1.9 million deaths per year worldwide, of which 1.5 million results from traumatic injury (3). Although 20% of the fatal cases of HS are considered avoidable, current practice has failed to improve the survival rate (4). Clinically, HS is treated with an expedited anatomic control of bleeding in conjunction with intravenous blood products, deliberate hypotension, antifibrinolytic therapy, and vasodilation (5, 6). Despite advances in clinical treatment aimed at the hypovolemic injury, patients who survive the initial HS insult have severe complications due to organ reperfusion injury, delayed infections, immune dysfunction, and the risk of developing organ, with incidences of 37.2%, or multiple organ failure (MOF), with incidences of 22.1% (7, 8).

Increasing evidence has proved that the modulation of innate immune responses is a promising therapeutic strategy for preventing and treating HS-induced MOF injury and complications (9). Soon after HS insult, exposure to exogenous pathogen-associated molecular pattern molecules (PAMPs) and endogenous damaged-associated molecular pattern molecules (DAMPs) extensively activate the innate immune defense, mainly comprising type II innate lymphoid cells (ILC2), CD4⁺ T cells, natural killer (NK) cells, eosinophils, dendritic cells (DCs), basophils, macrophages, neutrophils, and the complement cascade (10). The innate immune response initiated and propagated in response to HS triggers inflammatory and anti-inflammatory mechanisms within 30 min post-injury, followed by systemic immune response syndrome (SIRS) and counterbalancing anti-inflammatory response syndrome (CARS), which are related to organ injury and complications (11). The systemic parameters during HS suggest that restoration of innate immunity offers exciting and promising directions for developing novel therapeutics for HS-induced second injuries. Recently, compelling evidence has focused on the innate immune response for the monitoring and therapy of HS (8, 9, 12, 13). The emerging understanding is poised to revolutionize the treatment of HS through targeted immune modulators.

In this article, we firstly summarize recent advances in the pathomechanistic insights associated with the innate immune response following HS injury, then systematically detail the cutting-edge therapeutic strategies used in the past decade regarding the innate immune regulation in this field, such as mesenchymal stem cells (MSCs), MSC-derived exosomes, MSC-derived extracellular vesicles (MSC-EVs), MSC-derived soluble factors (FS-MSC), genetic approaches, antibody therapy, small molecule inhibitors, natural medicine, mesenteric lymph (ML) drainage, vagus nerve stimulation (VNS), hormones, glycoproteins, and others. We also reviewed clinical studies on the regulation of immunity for treating HS and assessed the potential of immune regulation concerning a translation from basic research to clinical practice. Combining these therapeutic strategies with an improved understanding of how the innate immune system responds to HS could help to identify and develop targeted therapeutic modalities that mitigate severe organ dysfunction, improve patient outcomes, and reduce mortality due to HS injury.

Innate immune response to HS

Increasing experimental and clinical evidence indicates that innate immunity is the predominant mediator in the pathophysiology of HS injury that unequivocally leads to organ damage and failure. The innate immune activation and immunosuppression responses to HS injury obtained in clinical trials and preclinical experiments are summarized in Figure 1.

Figure 1

At the site of hemorrhage, the immune system is challenged with “alarmins”, among which exogenous PAMPs are expressed on invading microorganisms and endogenous DAMPs are released from damaged and host cells, and include mitochondrial DNA, cold-inducible RNA-binding protein (CIRP), high mobility group box 1 (HMGB1), interleukin (IL)-25, IL-33, mitochondrial N-formyl peptides (F-MIT), and F-Actin (14–16). These “alarmins” are recognized by distressed immune cells through groups of pattern-recognition receptors, including toll-like receptors (TLRs), receptors of advanced glycation end products (RAGEs), C-type lectin receptors, and complement receptors (17). The excessive proinflammatory response SIRS and parallel immunosuppression CARS are induced after these damage molecules engage with their corresponding receptors, which is characterized by the release of cytokines, chemokines, complement factors, and coagulation proteins, as well as activation of innate immune cells (18). In terms of negative feedback, the excessive innate immune response can promote the circulation of new DAMPs, thereby amplifying a vicious cycle of cell and tissue injuries (19, 20).

During the development of HS, the innate immune cells act as the first line of defense, providing a rapid response to pathogens or danger signals through pattern recognition receptors (21). One of the first innate immune cell types to the site of injury is antigen-presenting cells, including tissue-resident macrophages, which sense damaging molecules and then differentiate from M1-type macrophages that secrete proinflammatory factors (TNF-α, IL-1β, IL-6, and interferon-γ) to M2-type macrophages that secrete anti-inflammatory factors (IL-10, IGF-1, and TGF-β) (22). In addition to defending against pathogens, macrophages are crucial to the maintenance of tissue homeostasis (23). Indeed, data suggest that the macrophage phenotype can correspondingly switch from M1-type macrophages, polarized by Th1 cytokines (GM-CSF, TNF-α, and interferon-γ), to M2-type macrophages, polarized by Th2 cytokines (IL-4 and IL-13) to deal with tissue repair (24, 25). Interestingly, neutrophils also regulate T cell function, and the M1-to-M2 macrophage switch represents a central element in the clearance of neutrophils by efferocytosis (26–28).

DCs are another type of antigen-presenting cell, which deliver antigens to T and NK cells. DCs show rapid responsiveness to pathogens or danger signals, which is followed by the secretion of TNF-α, interferon (IFN)-α, IFN-β, as well as IL-6 within a few hours after HS (29). The activation of T lymphocytes by DCs or danger signals is essential in exaggerating inflammation and subsequent immunosuppression (30). CD4⁺ T cells are the primary lymphocytes involved in HS injury and are classically divided into four categories: Th1, Th2, Th17, and T regulatory (Treg) cells (31). Treg cells can suppress T-cell activation and Th1 cytokine production after injury. Data suggest that HMGB1 binding to RAGE, TLR4 and TLR9 can promote the activation of DCs, CD4⁺ T, CD8⁺ T, Th17, and Treg cells in response to HS injury (32–34). The imbalance of Th17/Treg has been suggested to be positively correlated with the degree of acute liver injury (35). The balance of Th1/Th2 is attributed to conversion to type 2 responses during HS development (36–38). DCs subject to HS were more inclined to polarize naive CD4⁺ T cells into Th2 and Treg cells, consistent with the clinically observed immunosuppressive phenomena in severe patients (39). Clinically, the peak of organ damage and MOF occurs within the 3 days of HS, with lung failure being the most common (40, 41).

Taken together, innate immunity is activated early after HS injury, and cross-talk between various immune cells ultimately results in MOF. Many attempts of therapeutic strategies focusing on the innate immune regulation in preclinical and clinical studies have achieved promising results in reducing tissue injury, organ dysfunction, and ultimately mortality due to HS.

New insights into HS therapeutics with innate immune regulation

Stem cell therapy in HS

Stem cells possess a remarkable potential for developing new cell-based treatments in the context of HS by modulating local and systemic deleterious immune responses (42, 43). Table 1 shows the main stem cell-related therapeutic strategies in the HS model in order of stem-cell type: MSC (MSCs, MSC-EVs, FS-MSC, MSC-derived exosomes, and IL-1β primed MSC), adipose-derived stem cells, and neutrophil progenitors. Each of these therapeutic strategies is discussed in detail below.

MSCs are multipotent stem cells, which are commonly used as a clinical cell therapeutic strategy for immunomodulation and tissue repair (9, 56). Treg cells, an immunosuppressive T cell subset, are essential for maintaining immune homeostasis and tolerance (57). In a rat model of unilateral lung contusion followed by HS, impaired wound healing and lung structure were improved by MSCs treatment by increasing the Treg cell population (44, 45). Cell-based therapies using MSCs or MSC-EVs are beneficial for improving neurologic outcomes and lung injury in animal models of HS (9). Moreover, in an HS-induced mild lung injury rat model, leukocyte infiltrates (CD68⁺ and MPO⁺ cells) were significantly reduced in the lung after treatment with MSCs (46). The latest transcriptome data demonstrated that treatment with MSCs or MSC-EVs was associated with the inactivation of inflammation-chemokine and cytokine pathways in the lung of HS mice (47). In a porcine model of HS, the neuroprotective and neurorestorative properties observed in MSC-EVs treatment were also associated with the attenuation of inflammation-related transcription in the brain (48).

A previous study showed that IL-10, an immunoregulatory cytokine, binds to the IL-10 receptor and inhibits inflammation following HS (58, 59). Yunwei Zhang et al. found that IL-10-deficient MSCs lost the protective function compared to WT MSCs in an HS-induced hepatic injury model (49). Another experiment indicated that MSC-EVs carrying IL-10 as cargo were mainly taken up by macrophages in the liver, mediating M2-type macrophage polarization and consequent immunosuppression in HS-induced hepatic injury (49). Neutrophils are the first innate immune cells against pathogens due to their array of microbicidal activities (60, 61). Clinically, the drop in circulating neutrophils is positively correlated with the occurrence of MOF (62, 63). FS-MSCs have an immunomodulatory action through paracrine activity by secreting anti-inflammatory cytokines and growth factors (64). Recent studies have shown that treatment with FS-MSCs significantly reduced inflammation and lung neutrophil infiltrates in an HS-induced rat model (50).

An early single dose of exosomes derived from MSC treatment has been shown to attenuate neurological injury by decreasing IL-1, IL-6, and IL-18, and increasing granulocyte-macrophage colony-stimulating factor (GM-CSF) levels in the Yorkshire swine model of HS (51). Additionally, the administration of human MSC-derived exosomes induces transcriptomic changes of neuroinflammation after HS injury in swine (52). In several in vitro and in vivo studies, IL-1β priming maximized the immunomodulation effect of MSCs by regulating IL-6 and IL-8 expression and influencing the polarization of peritoneal macrophages (65, 66). Moreover, systemic cytokines (IL-1α, IL-6, and IL-10) and the programmed cell death receptor (PD)-1/PD-L1 axis were decreased by IL-1β-primed MSCs on monocytes and granulocytes in HS-induced kidney and liver injury model (53). Similarly, the IL-6 concentration also decreased with adipose-derived stem cell treatment in HS-induced liver injury (54). In rodent models of HS, it has been demonstrated that, in addition to suppressive proinflammatory cytokines in the lungs, there is an increase in neutrophil migration into the airspace from the bone marrow after neutrophil progenitor transplant, which can be used in the treatment and prevention of secondary infection following HS (55).

Indeed, several studies—mostly in rodents but also in porcine—have concluded that MSCs, MSC-EVs, FS-MSCs, MSC-derived exosomes, IL-1β-primed MSCs, adipose-derived stem cells, and neutrophil progenitors can relieve lung, neurologic, kidney, and liver injury by regulating innate immunity (Figure 2, Table 1). The innate immune processes involved in the above effects include reducing the leukocyte and neutrophil infiltrate, increasing the Treg population, mediating M2-type macrophage polarization and consequent immunosuppression, and inactivating inflammatory chemokines and cytokines (Figure 2, Table 1). These stem cell-related therapeutic strategies represent a potential opportunity for treating HS-induced second injuries.

Figure 2

Antibody therapy and genetic approaches in HS

IL-6 plays a prominent role in the differentiation from Th1 to Th2 in the development of HS (67). The secretion of IL-6 is positively correlated with the prognosis patients with shock and organ dysfunction (68, 69). Zhang Yong et al. reported that treatment with anti-mouse IL-6 monoclonal antibody immediately before resuscitation can prevent Th2 cytokine production, suppress the lymphocyte response, reduce the level of IL-10, keratinocyte-derived chemokine (KDC), monocyte chemoattractant protein 1(MCP-1), and macrophage inhibitory protein 1 (MIP-1) in a mouse model combining HS and lower-extremity injury (67). The mucosal address in cell adhesion molecule-1 (MAdCAM-1), a critical mediator of the early innate immune response to HS, mainly mediates lymphocyte recruitment to the gut during the inflammatory storm phase (70–72). This observation is supported by a finding that antibody blockade of MAdCAM-1 can decrease the secretion of IL-1β, IL-6, and TNF-α, reduce lymphocyte infiltration, ameliorate intestinal barrier dysfunction, and prolong survival (70). B and T lymphocyte attenuator (BTLA), a receptor that is structurally similar to PD-1, is expressed on T lymphocytes, B lymphocytes, monocytes, macrophages, and DCs (73, 74). A previous study showed that treatment with the anti-BTLA monoclonal [6A6] antibody (25μg/g body weight) can abolish HS followed by sepsis-induced reduction of cytokines and chemokines (TNF-α, IL-12, IL-10, KC, MIP-2, MCP-1) and decreased recruitment of neutrophils, macrophages, and DCs to the peritoneal cavity, which in turn relieve organ injury and reduce mortality (75).

Clinical studies have shown patients with HS with a poor prognosis within 24 h after admission have higher type 2 cytokines in serum, such as IL-5 (76). IL-33-stimulated ILC2, the resident innate lymphocytes that potently regulate host immunity in the lung, are the primary source of type 2 cytokines response to HS injury (34, 77). A recent finding has shown that anti-IL-5 antibody, IL-33, or ILC2 deletion, significantly increased IL-5 expression in neutrophils and decreased lung injury scores at 6 h in the HS-induced mice injury model (77). DAMPs can activate systemic inflammation and organ injury in HS through binding to TLR2 on immune cells (78). Similarly, anti-TLR2 monoclonal antibody or TLR2^-/- mice exhibited significantly less liver damage, and lower NF-κB and inflammatory cell infiltrate in HS at 20 h (78). Consistently, the phenotype of TLR2^-/- mice shows reduced intestinal injury accompanied by reduced complement (CD55, Factor H, and C3) and inflammatory (IL-12, IL-6, and TNF-α) factors, compared to wild-type mice (79).

Extracellular CIRP, an 18-kDa RNA chaperone protein, acts as an endogenous proinflammatory mediator, binds to TLR4, and leads to mitochondrial DNA fragmentation that triggers innate immunity and inflammatory responses in patients with HS (17, 80). Continuity studies demonstrated that the purified recombinant murine CIRP (rmCIRP) induces cytokine release in macrophages and deficiency or blockade of CIRP using antisera leads to attenuated TNF-α and IL-6 release, neutrophil accumulation, and lethality in HS injury (17, 80). Interestingly, wound-associated TNF-α enhancement and neutrophil infiltration is also attenuated in CIRP^-/- mice compared to WT mice (81). Mitochondrial DNA binds to the stimulator of interferon genes (STING) as a ligand, activating ype I interferon and proinflammatory cytokines-producing signals (82, 83). Kehong Chen et al. reported that the HS-induced increase in IL-6 and IFN-β levels in the serum and the high mRNAs expression of TNF-α, IL-6, and IL-1β in the lung were significantly counteracted by STING knockout, which suggests that the absence of STING significantly reduces inflammation and lung injury after HS (84).

Many studies have focused on the role of PD-1 and its ligand, PD-L1 (B7H1) in the cellular immunotherapy (85–87). The population of PD-1⁺ blood leukocytes in patients is positively correlated with interleukin levels in the serum, which suggests that PD-1 is a key indicator in the assessment of HS-induced immune dysfunction (87). Indeed, in terms of immune regulation, animals deficient in PD-1 or PD-L1 expression exhibited an attenuation in the neutrophil influx in HS injury, while PD-L1 knockout produced a marked suppression in the secretion of TNF-α, IL-6, and MCP-1, which were consistently elevated induced by HS in the WT mice group (88).

Clinical and preclinical studies have observed that nuclear factor-erythroid 2 p45-related factor-2 (Nrf2), a major mediator in innate immunity and inflammation, is significantly increased in the leukocytes collected from patients with HS (89–92). Haige Zhao et al. reported that HS-induced secretion of HMGB1, L-6, IL-1β, and TNF-αwere higher at 2 h in Nrf2 knockout mice (92). Likewise, Nrf2-KO offers no benefit over the hepatoprotection of remote ischemic conditioning in reductions in HS-induced TNF-α and IL-6 (93).

CD226, a costimulatory adhesion molecule expressed on both immune and endothelial cells, can regulate immune metabolic activity and function (94, 95). Recent studies have illustrated that CD226 deficiency in vascular endothelial cells can alleviate HS-induced intestinal damage and the inflammatory response (96). Emerging evidence shows that microRNAs play essential roles in pathophysiological responses by regulating inflammation and immunity (97, 98). Moreover, data suggest that miR-18b-5p knockdown notably reduced the levels of SOD1, iNOS, and IL-6 in macrophages, decreased the M1/M2 ratio of macrophages, and reduced the Th1/Th2 ratio of CD4⁺ T cells in splenic tissues after HS injury (99).

Significant advances have been made in the identification of immune therapies for HS injury, including antibodies (anti-IL-6, anti-TLR2, anti-IL-5, anti-IL-BTLA, and anti-MAdCAM-1), RNAi-based deficiency (PD-1, CD226, and miR-18b-5p), and gene knockout (TLR2, IL33, CIRP, or STING). In summary, these antibody therapies and genetic approaches for HS are associated with a potent innate immune response that not only regulates the levels of inflammatory factors, the lymphocyte influx, and neutrophil infiltration, but also reduces complement, the ratio of M1/M2 macrophages, the Th1/Th2 ratio in CD4⁺ T cells, and increases recruitment of DCs (Figure 3 and Table 2).

Figure 3

Small molecule inhibitor or agonist therapy in HS

As a master alarm system and a major fluid defense system of innate immunity after HS injury, the complement cascade can be rapidly activated by DAMPs or PAMPs, and lead to elevated plasma levels of complement activation products such as complement factor 1 (C1), complement factor 3 (C3) and complement factor 5 (C5) (100). As reviewed earlier, such exuberant complement activation evokes systemic inflammation, which is associated with increased susceptibility to infections and HS-induced MOF (8, 101). Early studies have shown that C3 deficiency attenuates HS-related hepatic injury and SIRS (102). The therapeutic inhibition of C3 by C3 inhibitor compstatin-40 (Cp40) is capable of improving immune, coagulation, and organ (kidney and intestine) functions by decreasing IL-6, MIF, IL-1RA, MIP-1, MCP-1, and IFN-γ (103). Another C3 inhibitor-soluble form of CR1 (sCR1) was confirmed to significantly mitigate the over-expression of NO, ET-1, TNF-α, and reactive oxygen species in serum to relieve vascular hyperreactivity in HS rats (104). Recombinant human C1-esterase inhibitor (rhC1-INH) has been found to particularly reduce tissue damage (kidney, gut, and lung), tissue complement activation, and cytokine release in an HS-induced porcine injury model (105). Additionally, the alternative complement activation in response to HS injury can induce macrophage infiltration and IL-12 secretion in the intestine (106). Multiple studies have indicated that treatment with complement inhibitors (C5 receptor antagonist or cobra venom factor) can significantly attenuate HS-induced intestinal injury (107–109). Furthermore, the mucosal damage, macrophage infiltration, and intestinal inflammation induced by HS injury were decreased by reducing leukotriene B4, IL-12p40, and TNF-α in the absence of IL-12p70 or treatment with complement receptor 2-targeted factor H (CR2-fH), a targeted inhibitor of the alternative complement pathway (106).

In addition to inhibitors targeting complement, many inhibitors targeting key proteins of innate immunity decrease HS-induced organ dysfunction. Recent studies have indicated that early intravenous treatment of tranexamic acid, a serine protease inhibitor, can protect the intestinal barrier by inhibiting neutrophil extracellular trap formation in the development of HS (110). CIRP acts as a DAMP to activate innate immunity and increases complications caused by HS (17). CIRP-derived oligopeptide-23 (C23) is homologous to the human CIRP protein (Ser110-Glu125) that binds to the CIRP receptor with high affinity and inhibits the secretion of TNF-α (111). Fangming Zhang et al. reported that the mRNA levels of IL-1β, TNF-α, and IL-6 in the lungs were reduced by adjuvant treatment with C23 (8 mg/kg) in HS-induced lung injury (111). Cyclosporine A (CsA) acts as a calcineurin inhibitor that participate in the innate immune response to pathogens in an inflammation storm (112). Some studies have shown that CsA could increase the survival time of HS rats by inhibiting proinflammatory cytokine production (IL-6) and reducing liver injury (113, 114).

Emerging evidence suggests that treatment with HDAC inhibitors (HDACIs) can attenuate MOF and improve early survival in animal models of HS by restoring “acetylation homeostasis” of histones and inducing transcriptional activation (115, 116). Transcriptomic studies in peripheral blood mononuclear cells (PBMC) and brain tissue suggested that valproic acid (VPA, one of HDACIs) can reduce HS-induced neurologic injury by downregulating genes associated with cell death and inflammation (IL-6, TLR4, JAK2, NLRP1, TNFα, IL-1α, IL-1B, NF-κB) (117, 118). In addition, treatment with VPA (150 mg/kg) significantly decreased brain lesion size and improved neurologic recovery by activating nuclear factor- k B (NF-κB) and degrading of cytosolic IκB in Yorkshire swine models of HS (119). Elizabeth A. Sailhamer et al. demonstrated that suberoylanilide hydroxamic acid (SAHA), one of HDACIs, can normalizes inflammatory cytokines (TNFα and IL-1β) levels by acetylating the transcription factor NF-κB following HS in the rats (120).

FTY720, an immunomodulator targeting receptors of sphingosine 1-phosphate (S1P), which can disrupt lymphocyte trafficking, prevent lymphocytes from accumulating in secondary lymphoid organs, and decrease lymphocytes in the blood circulation (121, 122). Jason S. Hawksworth et al. reported that FTY720 (0.3 mg/kg) could sequestrate the central lymphocytes, resulting in attenuation in innate cellular and signal activation following HS in a swine liver and lung injury model (123). FTY720 (1 mg/kg) has also been shown to reduce HS-induced MOD syndromes, red cell injury, and neutrophil priming in a rat model (124). The direct administration by a receptor agonist can block the binding of TLR ligands with their receptor, interfere with intracellular signaling molecules, and prevent signal amplification, which is a promising approach for treating HS-induced immune dysregulation. Xu Ding et al. reported that macrophage-activating lipopeptide-2 (MALP-2), as an agonist of TLR, given at the earliest can reduce pulmonary damage and polymorphonuclear neutrophil infiltration in an HS mouse model (125).

Latest studies have shown that some activators, such as sulforaphane, an Nrf2 pathway agonist, can modulate immunity against HS damage (126). Weiqiang Liang et al. demonstrated that sulforaphane, a potential immune modulator, could protect the liver from HS-induced inflammation storm by decreasing the secretion of TNF-α, MCP-1, KC/CXCL1, IL-6, and IL-10 and abolishing neutrophil infiltration in kupffer cells (126). Moreover, in a mouse HS model, sulforaphane administration reduced lung and liver injury via down-regulating pro-inflammatory cytokines, such as TNF-α, COX-2, iNOS, and IL-1β (127, 128).

As discussed above, small molecule inhibitors, especially complement-related target inhibitors, inhibitors of serine protease, CIRP, sphingosine-1-phosphate, toll-like receptors, mPTP, and agonists of the Nrf2 pathway, can reduce HS-induced liver, kidney, intestinal, renal, and lung and vascular hyperreactivity injury in monkey, swine, and rodent animal models by modulating innate immune responses (Figure 4, Table 3).

Figure 4

Natural medicine therapy for HS

Increasing research has confirmed the role of resveratrol, a natural polyphenol widely found in plants and fruits, in improving survival and prolonging lifespan following HS by improving immune function and reducing inflammation (129, 130). Phosphorylation and acetylation on the p65 subunit of NF-κB regulate the inflammatory cascade (131). In the HS-induced rat injury model, the ratio of the phosphorylated p65 subunit of NF-κB to the unphosphorylated form demonstrated a noticeable decline following resveratrol treatment (18). Resveratrol also counteracts the increase in gene expression and plasma secretion levels of IL-2, IL-6, IL-10, TNF-α, and MIP-1α at 2 h following HS in heart tissue (18). It has been reported that the release of proinflammatory cytokines caused by HS, participates in the development of kidney injury (132). Ophiopogonin A, an effective active component extracted from ophiopogonis radix, can dose-dependently downregulate the levels of iNOS, TNF-α, IL-1β and IL-6, and decrease HS-induced renal injury (133).

Intestinal DCs play essential roles in regulating the function of the intestinal immune barrier and intestinal bacterial translocation (134). Experimental evidence suggests that treatment with allicin, a thiosulfonate extract from freshly minced garlic, can block intraintestinal bacterial translocation and reduce the permeability of the intestinal barrier by assisting the immunologic barrier function of the ML node and facilitating the maturation of DCs (135, 136). Ursolic acid, a natural pentacyclic triterpenoid carboxylic acid isolated from uncaria rhynchophylla, reduces immune-mediated lung inflammation, assists human DCs via TLRs, and accelerates the production of IFNγ by CD4⁺ T cells (137, 138). Additionally, ursolic acid suppresses superoxide production in activated neutrophils and restrains HS-induced hepatic and lung injuries in rats (139). The development of complications from HS is accompanied by the activation of neutrophils (77, 140). In the rat HS model, the neutrophilic oxidative stress and lung injury were restrained after administration of osthol, a natural coumarin found in traditional medicinal plants (141).

In conclusion, natural medicines, such as polyphenol, saponins, thiosulfonate, carboxylic acid, and coumarin represent an essential therapy against HS-induced injury in terms of regulating immune processes, including subsiding inflammatory cytokine release, assisting the immunologic barrier function of the ML node, facilitating DC maturation, reducing superoxide production in activated neutrophils, and attenuating neutrophil-dominated inflammation, to improve cardiac function, block intraintestinal bacterial translocation, and relieve hepatic, lung, and kidney tissue injury (Figure 5, Table 4).

Figure 5

Other therapies in HS

Other therapies, such as physical therapy (post-shock ML drainage, VNS, stellate ganglion block), glycoprotein, fatty acids, and inorganic compounds can also be used to modulate immunity against HS injury (Figure 5, Table 5). Previous studies have shown that the diversion of the ML or lymphatic duct ligation can reduce vascular permeability, subside systemic neutrophil priming, and decrease lung injury in HS models (143). It has been recently shown that post-shock ML drainage can decrease the levels of the T lymphocyte subgroup, including the population of CD3⁺ cells, CD3⁺ cells, CD4⁺ cells, and CD4⁺CD25⁺ cells, and reduce IFN-γ and IL-4 secretion in the HS rat model at 3 h after resuscitation, which suggests that post-shock ML drainage can markedly improve hyperimmunity occurred at early stages (142). Conversely, exosomes isolated from post-shock ML significantly increase lung injury by recruitment of inflammatory cells to the alveolar space and lung parenchyma, inducing mRNA expression of NF-κB, iNOS, TNF-α, and CINC-1 during HS (150).

The continuous migration of CD103⁺ DCs from the intestine to the ML nodes is considered to induce Treg cell maturation and promote tolerance to intestinal inflammation (151, 152). The balance of Treg and Th17 cells determines the intestinal tolerance to inflammation and immune response (153). Previous studies have demonstrated that VNS prevents HS-induced impairment in intestinal blood flow, alters the DC profile, and prevents incompleteness of the gut barrier in the ML (154–158). Additionally, Koji Morishita et al. reported that VNS could promote tolerance to HS-induced inflammation by increasing the CD103⁺ DC population in the ML and facilitating the ratio of Treg cells to Th17 cells (143). VNS has also been shown to increase the level of IL-10 and decrease HS-induced lung and gut barrier injury, with a marked decrease in the mRNA level of TNF-α, IL-6, NF-κB, and MPO (144, 145). Previous studies have shown that stellate ganglion block (SGB), a standard method of blocking sympathetic nerves, can reduce intestinal barrier dysfunction and prolong the survival time in the HS rat model (159). The latest research shows that SGB administration significantly normalized the population of CD4⁺ T cells and the level of IL-2, IL-4, and TNFα-induced protein 8 like 2 (TIPE2) in the development of HS (146).

Lactoferrin, as a pleiotropic glycoprotein, was proven to limit HS-induced gut injury and inhibit the biological activity of ML by enhancing the gastrointestinal barrier and assisting mucosal immunity (147). Talactoferrin, a unique recombinant form of human lactoferrin and an oral DC cell-mediated immunotherapy, has demonstrated safety and preliminary efficacy in clinical trials (160–162). It has been recently shown that talactoferrin (1000 mg/kg/day) pretreatment 5 d before being subjected to HS injury has gut-protective effects by reducing the respiratory burst activity of lymph (147). Intestinal mucosa innate immunity is involved in removing pathogenic bacteria and alleviating intestinal injury (163). Feng Tian et al. reported that n-3 polyunsaturated fatty acids (PUFAs) could restore the function of the intestinal barrier by improving the innate immunity of the intestinal mucosa, increasing the expression of lysozyme, mucin 2, and IL-4, and stabilizing the intestinal microbiota in mice after HS (148). An early study revealed that hydrogen sulfide could increase survival in rodent models of lethal hemorrhage (164). Moreover, Dunquan Xu et al. demonstrated that sodium hydrosulfide administration could protect lungs against HS injury by suppressing the levels of IL-6, TNF-α, and HMGB1 in rat bronchoalveolar lavage fluid (149).

In summary, increasing therapeutic approaches to HS have been verified, focusing on various mechanisms involving innate immunity. These therapeutic approaches restore the thymus, lung, and gut. In addition to regulating the secretion of inflammatory cytokines and chemokines (IFN-γ, IL-4, NF-κB, iNOS, TNF-α, IL-10, IL-6, IL-2, and CINC-1), these novel therapeutic options for treating HS to restore critical organ function mainly rely on regulating the population of innate immune cells, involving T lymphocyte subgroup, CD4 ⁺ T cell, Treg cells, monocytes, Th17 cells and DC cells (Figure 5, Table 5).

Clinical opportunities of innate immune modulation in HS

Although some attempts at targeting innate immunity against HS injury and subsequent organ damage in preclinical models have been successful, only a few clinical trials have evaluated the treatment strategies with immune-related indicators as primary or second outcome measures in patients with HS.

Dexmedetomidine (Dex; α2 adrenergic receptor agonist) targeted activation of α2 receptors can produce sedative, analgesic, antisympathetic, and hemodynamic effects (165). New clinical evidence indicates that early intervention with Dex can effectively prevent postoperative renal insufficiency or renal failure and improve microcirculation in patients with HS requiring surgery, mainly by inhibiting the release of oxygen free radicals, IL-6, and IL-8 (166). Another promising therapeutic compound is ulinastatin, a glycoprotein derived from human urine; combined with thymosin α1, ulinastatin improves the survival rate of patients with bacterial infection by significantly increasing the CD4⁺CD8⁺ population and restoring the balance between proinflammatory mediators (TNFα, IL-1β, IL-6, and IL-8) and anti-inflammatory cytokines (IL-4 and IL-10) (167). Park et al. reported that ulinastatin administration (300,000 IU) neutralizes the serum polymorphonuclear leukocyte elastase (PMNE) levels and decreases the secretion of TNF-α and IL-6 in trauma patients with HS at 48 h after administration (168). Pre-clinical studies have certificated the benefit of estrogen in reducing MOF injury and mortality in HS (169, 170). More importantly, the levels of Treg cell, monocytes, and inflammatory factors were significantly balanced in patients with HS after receiving estrogen treatment (171). Conversely, the results of one clinical study on the effect of remote ischemic conditioning on trauma patients with HS using immune regulation (neutrophil activity and plasma inflammatory factor expression) as the primary outcome measures were disappointing, limited by prolonged emergency transport time and delayed application of therapy (ClinicalTrials.gov Identifier: NCT02071290). One therapeutic method for HS injury currently under clinical investigation is hypertonic resuscitation, with the primary outcome measures being neutrophil activation, coagulation parameters, and monocyte activation (ClinicalTrials.gov Identifier: NCT00750997).

Most of the clinical studies of HS therapy have focused on resuscitation fluid and modulators (nitroglycerine, polydatin, vasopressin, estrogen, and the combination of norepinephrine with octreotide) using hospital admission rate, urinary output, blood pressure, heart rate, Glasgow coma scale value, microcirculatory flow index, perfusion index, mean arterial pressure, survival, or organ dysfunction as the primary outcome measures (ClinicalTrials.gov Identifier: NCT01780129, NCT03891849, NCT03235921, NCT01433276, NCT00379522, NCT00973102) (172–175). There remains an immense need to validate these promising strategies targeting innate immunity against HS injury in non-human primate models, organoid models, and clinical patients.

Conclusion and prospects

Increasing experimental and clinical evidence has contributed to a profound understanding of the pathophysiology of HS injuries in recent years. Furthermore, regulation of innate immunity is recognized as an attractive pharmacological target offering encouraging future directions for the R&D of novel therapeutics. In this regard, numerous strategies, including MSCs, exosomes, genetic approaches, antibody therapy, small molecule inhibitors, and natural medicine, have been successfully employed for protection from HS damage and MOF in rodents, porcine, and non-human primate models. The immunomodulatory mechanisms of therapeutic approaches in HS injury discussed above are not only reflected in the regulation of inflammatory cytokines and chemokines but also in the balance of complement, DCs, macrophages polarization, T lymphocyte differentiation, and neutrophil infiltration.

The systematic and comprehensive research focus on HS injury and innate immunity regulation has led to many advances; however, gaps in the translation from basic research to clinic capability remain. As immune activation and immunosuppression are inseparable and sequential during the development of MOF in HS, the time point of starting and stopping therapeutic interventions is crucial. Furthermore, reliable monitoring of the remaining immunomodulatory functions of the intervening strategies within the HS-induced immunity response cascade are equally important. Ongoing studies should accelerate the progression of the most promising strategy targeting innate immunity to clinical trials in HS injury. Overall, the modulation of the innate immune response by specific intervening strategies might provide the key to closing the cascading damage resulting from the vicious danger response after HS injury.

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 82104432 and U19A2013), and the Science and Technology Development Plan Project of Jilin Province (Grant No. 202002053JC and 20200201419JC).

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1

  Cannon JW . Hemorrhagic shock. New Engl J Med (2018) 3784:370–9. doi: 10.1056/NEJMra1705649

  • CrossRef
  • Google Scholar

• 2

  Halmin M Chiesa F Vasan SK Wikman A Norda R Rostgaard K et al . Epidemiology of massive transfusion: A binational study from Sweden and Denmark. Crit Care Med (2016) 443:468–77. doi: 10.1097/CCM.0000000000001410

  • CrossRef
  • Google Scholar

• 3

  Lozano R Naghavi M Foreman K Lim S Shibuya K Aboyans V et al . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet (London England) (2012) 3809859:2095–128. doi: 10.1016/S0140-67361261728-0

  • CrossRef
  • Google Scholar

• 4

  Jiang SY Zhao YY Zhao XG . Potential role of therapeutic hypothermia in the salvage of traumatic hemorrhagic shock. Crit Care (2013) 173:318. doi: 10.1186/cc12559

  • CrossRef
  • Google Scholar

• 5

  Dutton RP . Haemostatic resuscitation. Br J Anaesthesia (2012) 109 Suppl 1:i39–46. doi: 10.1093/bja/aes389

  • CrossRef
  • Google Scholar

• 6

  Sperry JL Guyette FX Brown JB Yazer MH Triulzi DJ Early-Young BJ et al . Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. New Engl J Med (2018) 3794:315–26. doi: 10.1056/NEJMoa1802345

  • CrossRef
  • Google Scholar

• 7

  Mitra B Gabbe BJ Kaukonen KM Olaussen A Cooper DJ Cameron PA . Long-term outcomes of patients receiving a massive transfusion after trauma. Shock (2014) 424:307–12. doi: 10.1097/SHK.0000000000000219

  • CrossRef
  • Google Scholar

• 8

  Huber-Lang M Gebhard F Schmidt C Palmer A Denk S Wiegner R . Complement therapeutic strategies in trauma, hemorrhagic shock and systemic inflammation - closing pandora's box? Semin Immunol (2016) 283:278–84. doi: 10.1016/j.smim.2016.04.005

  • CrossRef
  • Google Scholar

• 9

  Valade G Libert N Martinaud C Vicaut E Banzet S Peltzer J . Therapeutic potential of mesenchymal stromal cell-derived extracellular vesicles in the prevention of organ injuries induced by traumatic hemorrhagic shock. Front Immunol (2021) 12:749659. doi: 10.3389/fimmu.2021.749659

  • CrossRef
  • Google Scholar

• 10

  von Burg N Chappaz S Baerenwaldt A Horvath E Bose Dasgupta S Ashok D et al . Activated group 3 innate lymphoid cells promote T-Cell-Mediated immune responses. Proc Natl Acad Sci USA. (2014) 11135:12835–40. doi: 10.1073/pnas.1406908111

  • CrossRef
  • Google Scholar

• 11

  Bortolotti P Faure E Kipnis E . Inflammasomes in tissue damages and immune disorders after trauma. Front Immunol (2018) 9:1900. doi: 10.3389/fimmu.2018.01900

  • CrossRef
  • Google Scholar

• 12

  Manson J Hoffman R Chen S Ramadan MH Billiar TR . Innate-like lymphocytes are immediate participants in the hyper-acute immune response to trauma and hemorrhagic shock. Front Immunol (2019) 10:1501. doi: 10.3389/fimmu.2019.01501

  • CrossRef
  • Google Scholar

• 13

  Wilson N Wall J Naganathar V Brohi K De'Ath H . Mechanisms involved in secondary cardiac dysfunction in animal models of trauma and hemorrhagic shock. Shock (Augusta Ga) (2017) 484:401–10. doi: 10.1097/shk.0000000000000882

  • CrossRef
  • Google Scholar

• 14

  Wenceslau CF McCarthy CG Szasz T Goulopoulou S Webb RC . Mitochondrial n-formyl peptides induce cardiovascular collapse and sepsis-like syndrome. Am J Physiol Heart Circ Physiol (2015) 3087:H768–77. doi: 10.1152/ajpheart.00779.2014

  • CrossRef
  • Google Scholar

• 15

  Itagaki K Kaczmarek E Lee YT Tang IT Isal B Adibnia Y et al . Mitochondrial DNA released by trauma induces neutrophil extracellular traps. PloS One (2015) 103:e0120549. doi: 10.1371/journal.pone.0120549

  • CrossRef
  • Google Scholar

• 16

  Simmons JD Lee YL Mulekar S Kuck JL Brevard SB Gonzalez RP et al . Elevated levels of plasma mitochondrial DNA damps are linked to clinical outcome in severely injured human subjects. Ann Surg (2013) 2584:591–6. doi: 10.1097/SLA.0b013e3182a4ea46

  • CrossRef
  • Google Scholar

• 17

  Qiang X Yang WL Wu R Zhou M Jacob A Dong W et al . Cold-inducible rna-binding protein (Cirp) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat Med (2013) 1911:1489–95. doi: 10.1038/nm.3368

  • CrossRef
  • Google Scholar

• 18

  Lu S Aguilar A Subramani K Poulose N Ayub A Raju R . Alteration of cytokine profile following hemorrhagic shock. Cytokine (2016) 81:35–8. doi: 10.1016/j.cyto.2016.01.022

  • CrossRef
  • Google Scholar

• 19

  Huber-Lang M Lambris JD Ward PA . Innate immune responses to trauma. Nat Immunol (2018) 194:327–41. doi: 10.1038/s41590-018-0064-8

  • CrossRef
  • Google Scholar

• 20

  Ma KC Schenck EJ Pabon MA Choi AMK . The role of danger signals in the pathogenesis and perpetuation of critical illness. Am J Respir Crit Care Med (2018) 1973:300–9. doi: 10.1164/rccm.201612-2460PP

  • CrossRef
  • Google Scholar

• 21

  Pantalone D Bergamini C Martellucci J Alemanno G Bruscino A Maltinti G et al . The role of damps in burns and hemorrhagic shock immune response: Pathophysiology and clinical issues. Review Int J Mol Sci (2021) 2213:7020. doi: 10.3390/ijms22137020

  • CrossRef
  • Google Scholar

• 22

  Xiang M Yuan Y Fan L Li Y Li A Yin L et al . Role of macrophages in mobilization of hematopoietic progenitor cells from bone marrow after hemorrhagic shock. Shock (2012) 375:518–23. doi: 10.1097/SHK.0b013e318249b81d

  • CrossRef
  • Google Scholar

• 23

  Mehta AK Kadel S Townsend MG Oliwa M Guerriero JL . Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol (2021) 12:643771. doi: 10.3389/fimmu.2021.643771

  • CrossRef
  • Google Scholar

• 24

  Gordon S Martinez FO . Alternative activation of macrophages: Mechanism and functions. Immunity (2010) 325:593–604. doi: 10.1016/j.immuni.2010.05.007

  • CrossRef
  • Google Scholar

• 25

  Novak ML Koh TJ . Macrophage phenotypes during tissue repair. J Leukoc Biol (2013) 936:875–81. doi: 10.1189/jlb.1012512

  • CrossRef
  • Google Scholar

• 26

  Jackaman C Tomay F Duong L Abdol Razak NB Pixley FJ Metharom P et al . Aging and cancer: The role of macrophages and neutrophils. Ageing Res Rev (2017) 36:105–16. doi: 10.1016/j.arr.2017.03.008

  • CrossRef
  • Google Scholar

• 27

  Keeley T Costanzo-Garvey DL Cook LM . Unmasking the many faces of tumor-associated neutrophils and macrophages: Considerations for targeting innate immune cells in cancer. Trends Cancer (2019) 512:789–98. doi: 10.1016/j.trecan.2019.10.013

  • CrossRef
  • Google Scholar

• 28

  Scapini P Cassatella MA . Social networking of human neutrophils within the immune system. Blood (2014) 1245:710–9. doi: 10.1182/blood-2014-03-453217

  • CrossRef
  • Google Scholar

• 29

  Zettel K Korff S Zamora R Morelli AE Darwiche S Loughran PA et al . Toll-like receptor 4 on both myeloid cells and dendritic cells is required for systemic inflammation and organ damage after hemorrhagic shock with tissue trauma in mice. Front Immunol (2017) 8:1672. doi: 10.3389/fimmu.2017.01672

  • CrossRef
  • Google Scholar

• 30

  Namas RA Mi Q Namas R Almahmoud K Zaaqoq AM Abdul-Malak O et al . Insights into the role of chemokines, damage-associated molecular patterns, and lymphocyte-derived mediators from computational models of trauma-induced inflammation. Antioxid Redox Signal (2015) 2317:1370–87. doi: 10.1089/ars.2015.6398

  • CrossRef
  • Google Scholar

• 31

  Wang P Jiang LN Wang C Li Y Yin M Du HB et al . Estradiol-induced inhibition of endoplasmic reticulum stress normalizes splenic Cd4 + T lymphocytes following hemorrhagic shock. Sci Rep (2021) 111:7508. doi: 10.1038/s41598-021-87159-1

  • CrossRef
  • Google Scholar

• 32

  Lohani N Rajeswari MR . Dichotomous life of DNA binding high mobility group Box1 protein in human health and disease. Curr Protein Pept Sci (2016) 178:762–75. doi: 10.2174/1389203717666160226145217

  • CrossRef
  • Google Scholar

• 33

  Liu GQ Zuo XH Jiang LN Zhang YP Zhang LM Zhao ZG et al . Inhibitory effect of post-hemorrhagic shock mesenteric lymph drainage on the Hmgb1 and rage in mouse kidney. Renal failure (2016) 381:131–6. doi: 10.3109/0886022X.2015.1105026

  • CrossRef
  • Google Scholar

• 34

  Zhang K Jin Y Lai D Wang J Wang Y Wu X et al . Rage-induced Ilc2 expansion in acute lung injury due to haemorrhagic shock. Thorax (2020) 753:209–19. doi: 10.1136/thoraxjnl-2019-213613

  • CrossRef
  • Google Scholar

• 35

  Zhang H Jiang Z Zhang L . Dual effect of T helper cell 17 (Th17) and regulatory T cell (Treg) in liver pathological process: From occurrence to end stage of disease. Int Immunopharmacol (2019) 69:50–9. doi: 10.1016/j.intimp.2019.01.005

  • CrossRef
  • Google Scholar

• 36

  Wang X Jiang Z Xing M Fu J Su Y Sun L et al . Interleukin-17 mediates triptolide-induced liver injury in mice. Food Chem Toxicol an Int J published Br Ind Biol Res Assoc (2014) 71:33–41. doi: 10.1016/j.fct.2014.06.004

  • CrossRef
  • Google Scholar

• 37

  Gupta DL Bhoi S Mohan T Galwnkar S Rao DN . Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with post traumatic sepsis. Cytokine (2016) 88:214–21. doi: 10.1016/j.cyto.2016.09.010

  • CrossRef
  • Google Scholar

• 38

  Yao F Lu YQ Jiang JK Gu LH Mou HZ . Immune recovery after fluid resuscitation in rats with severe hemorrhagic shock. J Zhejiang Univ Sci B (2017) 185:402–9. doi: 10.1631/jzus.B1600370

  • CrossRef
  • Google Scholar

• 39

  Zhang J Zhang Y Xu T Pan SJ Nie G Miao XY et al . Severe traumatic hemorrhagic shock induces compromised immune barrier function of the mesenteric lymph node leading to an increase in intestinal bacterial translocation. Am J Transl Res (2017) 95:2363–73. doi: 10.1002/ptr.5847

  • CrossRef
  • Google Scholar

• 40

  Sauaia A Moore EE Johnson JL Chin TL Banerjee A Sperry JL et al . Temporal trends of postinjury multiple-organ failure: Still resource intensive, morbid, and lethal. J Trauma Acute Care Surg (2014) 763:582–92. doi: 10.1097/TA.0000000000000147

  • CrossRef
  • Google Scholar

• 41

  Veith NT Histing T Menger MD Pohlemann T Tschernig T . Helping Prometheus: Liver protection in acute hemorrhagic shock. Ann Trans Med (2017) 510:206. doi: 10.21037/atm.2017.03.109

  • CrossRef
  • Google Scholar

• 42

  De Luca M Aiuti A Cossu G Parmar M Pellegrini G Robey PG . Advances in stem cell research and therapeutic development. Nat Cell Biol (2019) 217:801–11. doi: 10.1038/s41556-019-0344-z

  • CrossRef
  • Google Scholar

• 43

  Johnson TC Siegel D . Directing stem cell fate: The synthetic natural product connection. Chem Rev (2017) 11718:12052–86. doi: 10.1021/acs.chemrev.7b00015

  • CrossRef
  • Google Scholar

• 44

  Gore AV Bible LE Song K Livingston DH Mohr AM Sifri ZC . Mesenchymal stem cells increase T-regulatory cells and improve healing following trauma and hemorrhagic shock. J Trauma Acute Care Surg (2015) 791:48–52. doi: 10.1097/TA.0000000000000681

  • CrossRef
  • Google Scholar

• 45

  Gore A Bible L Livingston D Mohr A Sifri Z . Mesenchymal stem cells enhance lung recovery after injury, shock, and chronic stress. Surgery (2016) 1595:1430–5. doi: 10.1016/j.surg.2015.12.006

  • CrossRef
  • Google Scholar

• 46

  Pati S Gerber MH Menge TD Wataha KA Zhao Y Baumgartner JA et al . Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PloS One (2011) 69:e25171. doi: 10.1371/journal.pone.0025171

  • CrossRef
  • Google Scholar

• 47

  Potter DR Miyazawa BY Gibb SL Deng X Togaratti PP Croze RH et al . Mesenchymal stem cell-derived extracellular vesicles attenuate pulmonary vascular permeability and lung injury induced by hemorrhagic shock and trauma. J Trauma Acute Care Surg (2018) 842:245–56. doi: 10.1097/TA.0000000000001744

  • CrossRef
  • Google Scholar

• 48

  Bambakidis T Dekker SE Williams AM Biesterveld BE Bhatti UF Liu B et al . Early treatment with a single dose of mesenchymal stem cell derived extracellular vesicles modulates the brain transcriptome to create neuroprotective changes in a porcine model of traumatic brain injury and hemorrhagic shock. Shock (2022) 572:281–90. doi: 10.1097/SHK.0000000000001889

  • CrossRef
  • Google Scholar

• 49

  Zhang Y Zhang X Zhang H Song P Pan W Xu P et al . Viamesenchymal stem cells derived extracellular vesicles alleviate traumatic hemorrhagic shock induced hepatic injury il-10/Ptpn22-Mediated M2 kupffer cell polarization. Front Immunol (2021) 12:811164. doi: 10.3389/fimmu.2021.811164

  • CrossRef
  • Google Scholar

• 50

  Dias VL Braga KAO Nepomuceno NA Ruiz LM Perez JDR Correia AT et al . Soluble factors of mesenchimal stem cells (Fs-msc) as a potential tool to reduce inflammation in donor's lungs after hypovolemic shock. Jornal brasileiro pneumologia publicacao oficial da Sociedade Bras Pneumologia e Tisilogia (2021) 474:e20200452. doi: 10.36416/1806-3756/e20200452

  • CrossRef
  • Google Scholar

• 51

  Williams AM Wu Z Bhatti UF Biesterveld BE Kemp MT Wakam GK et al . Early single-dose exosome treatment improves neurologic outcomes in a 7-day swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg (2020) 892:388–96. doi: 10.1097/TA.0000000000002698

  • CrossRef
  • Google Scholar

• 52

  Williams AM Higgins GA Bhatti UF Biesterveld BE Dekker SE Kathawate RG et al . Early treatment with exosomes following traumatic brain injury and hemorrhagic shock in a swine model promotes transcriptional changes associated with neuroprotection. J Trauma Acute Care Surg (2020) 893:536–43. doi: 10.1097/TA.0000000000002815

  • CrossRef
  • Google Scholar

• 53

  Aussel C Baudry N Grosbot M Caron C Vicaut E Banzet S et al . Il-1beta primed mesenchymal stromal cells moderate hemorrhagic shock-induced organ injuries. Stem Cell Res Ther (2021) 121:438. doi: 10.1186/s13287-021-02505-4

  • CrossRef
  • Google Scholar

• 54

  Ashmwe M Penzenstadler C Bahrami A Klotz A Jafarmadar M Banerjee A et al . Secretome conveys the protective effects of ascs: Therapeutic potential following hemorrhagic shock? Shock (2018) 504:442–8. doi: 10.1097/SHK.0000000000001047

  • CrossRef
  • Google Scholar

• 55

  Cohen J Danise M Machan J Zhao R Lefort C . Murine myeloid progenitors attenuate immune dysfunction induced by hemorrhagic shock. Stem Cell Rep (2021) 162:324–36. doi: 10.1016/j.stemcr.2020.12.014

  • CrossRef
  • Google Scholar

• 56

  Spees JL Lee RH Gregory CA . Mechanisms of mesenchymal Stem/Stromal cell function. Stem Cell Res Ther (2016) 71:125. doi: 10.1186/s13287-016-0363-7

  • CrossRef
  • Google Scholar

• 57

  Ohkura N Sakaguchi S . Transcriptional and epigenetic basis of treg cell development and function: Its genetic anomalies or variations in autoimmune diseases. Cell Res (2020) 306:465–74. doi: 10.1038/s41422-020-0324-7

  • CrossRef
  • Google Scholar

• 58

  Minshawi F Lanvermann S McKenzie E Jeffery R Couper K Papoutsopoulou S et al . The generation of an engineered interleukin-10 protein with improved stability and biological function. Front Immunol (2020) 11:1794. doi: 10.3389/fimmu.2020.01794

  • CrossRef
  • Google Scholar

• 59

  Kobbe P Lichte P Schreiber H Reiss LK Uhlig S Pape HC et al . Inhalative il-10 attenuates pulmonary inflammation following hemorrhagic shock without major alterations of the systemic inflammatory response. Mediators Inflammation (2012) 2012:512974. doi: 10.1155/2012/512974

  • CrossRef
  • Google Scholar

• 60

  Kupani M Pandey RK Mehrotra S . Neutrophils and visceral leishmaniasis: Impact on innate immune response and cross-talks with macrophages and dendritic cells. J Cell Physiol (2021) 2364:2255–67. doi: 10.1002/jcp.30029

  • CrossRef
  • Google Scholar

• 61

  Kraus RF Gruber MA . Neutrophils-from bone marrow to first-line defense of the innate immune system. Front Immunol (2021) 12:767175. doi: 10.3389/fimmu.2021.767175

  • CrossRef
  • Google Scholar

• 62

  Briggs GD Lemmert K Lott NJ de Malmanche T Balogh ZJ . Biomarkers to guide the timing of surgery: Neutrophil and monocyte l-selectin predict postoperative sepsis in orthopaedic trauma patients. J Clin Med (2021) 1010:2207. doi: 10.3390/jcm10102207

  • CrossRef
  • Google Scholar

• 63

  Schietroma M Pessia B Mattei A Romano L Giuliani A Carlei F . Temperature-Neutrophils-Multiple organ failure grading for complicated intra-abdominal infections. Surg infections (2020) 211:69–74. doi: 10.1089/sur.2019.092

  • CrossRef
  • Google Scholar

• 64

  Ionescu L Byrne RN van Haaften T Vadivel A Alphonse RS Rey-Parra GJ et al . Stem cell conditioned medium improves acute lung injury in mice: In vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol (2012) 30311:L967–77. doi: 10.1152/ajplung.00144.2011

  • CrossRef
  • Google Scholar

• 65

  Carrero R Cerrada I Lledo E Dopazo J Garcia-Garcia F Rubio MP et al . Il1beta induces mesenchymal stem cells migration and leucocyte chemotaxis through nf-kappab. Stem Cell Rev Rep (2012) 83:905–16. doi: 10.1007/s12015-012-9364-9

  • CrossRef
  • Google Scholar

• 66

  Fan H Zhao G Liu L Liu F Gong W Liu X et al . Pre-treatment with il-1beta enhances the efficacy of msc transplantation in dss-induced colitis. Cell Mol Immunol (2012) 96:473–81. doi: 10.1038/cmi.2012.40

  • CrossRef
  • Google Scholar

• 67

  Zhang Y Zhang J Korff S Ayoob F Vodovotz Y Billiar TR . Delayed neutralization of interleukin 6 reduces organ injury, selectively suppresses inflammatory mediator, and partially normalizes immune dysfunction following trauma and hemorrhagic shock. Shock (2014) 423:218–27. doi: 10.1097/SHK.0000000000000211

  • CrossRef
  • Google Scholar

• 68

  Halbgebauer R Karasu E Braun CK Palmer A Braumuller S Schultze A et al . Thirty-Eight-Negative kinase 1 is a mediator of acute kidney injury in experimental and clinical traumatic hemorrhagic shock. Front Immunol (2020) 11:2081. doi: 10.3389/fimmu.2020.02081

  • CrossRef
  • Google Scholar

• 69

  Barayan D Abdullahi A Vinaik R Knuth CM Auger C Jeschke MG . Interleukin-6 blockade, a potential adjunct therapy for post-burn hypermetabolism. FASEB J (2021) 355:e21596. doi: 10.1096/fj.202100388R

  • CrossRef
  • Google Scholar

• 70

  Zhang H Besner G Feng J . Antibody blockade of mucosal addressin cell adhesion molecule-1 attenuates proinflammatory activity of mesenteric lymph after hemorrhagic shock and resuscitation. Surgery (2016) 1595:1449–60. doi: 10.1016/j.surg.2015.12.013

  • CrossRef
  • Google Scholar

• 71

  August KJ Chiang KY Qayed M Dulson A Worthington-White D Cole CR et al . Relative defects in mucosal immunity predict acute graft-Versus-Host disease. Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant (2014) 207:1056–9. doi: 10.1016/j.bbmt.2014.03.012

  • CrossRef
  • Google Scholar

• 72

  Habtezion A Nguyen LP Hadeiba H Butcher EC . Leukocyte trafficking to the small intestine and colon. Gastroenterology (2016) 1502:340–54. doi: 10.1053/j.gastro.2015.10.046

  • CrossRef
  • Google Scholar

• 73

  Mintz MA Felce JH Chou MY Mayya V Xu Y Shui JW et al . The hvem-btla axis restrains T cell help to germinal center b cells and functions as a cell-extrinsic suppressor in lymphomagenesis. Immunity (2019) 512:310–23.e7. doi: 10.1016/j.immuni.2019.05.022

  • CrossRef
  • Google Scholar

• 74

  Jones A Bourque J Kuehm L Opejin A Teague RM Gross C et al . Immunomodulatory functions of btla and hvem govern induction of extrathymic regulatory T cells and tolerance by dendritic cells. Immunity (2016) 455:1066–77. doi: 10.1016/j.immuni.2016.10.008

  • CrossRef
  • Google Scholar

• 75

  Cheng T Bai J Chung CS Chen Y Biron BM Ayala A . Enhanced innate inflammation induced by anti-btla antibody in dual insult model of hemorrhagic Shock/Sepsis. Shock (2016) 451:40–9. doi: 10.1097/SHK.0000000000000479

  • CrossRef
  • Google Scholar

• 76

  Namas RA Vodovotz Y Almahmoud K Abdul-Malak O Zaaqoq A Namas R et al . Temporal patterns of circulating inflammation biomarker networks differentiate susceptibility to nosocomial infection following blunt trauma in humans. Ann Surg (2016) 2631:191–8. doi: 10.1097/SLA.0000000000001001

  • CrossRef
  • Google Scholar

• 77

  Xu J Guardado J Hoffman R Xu H Namas R Vodovotz Y et al . Il33-mediated Ilc2 activation and neutrophil Il5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model. PloS Med (2017) 147:e1002365. doi: 10.1371/journal.pmed.1002365

  • CrossRef
  • Google Scholar

• 78

  Korff S Loughran P Cai C Fan J Elson G Shang L et al . Tlr2 on bone marrow and non-bone marrow derived cells regulates inflammation and organ injury in cooperation with Tlr4 during resuscitated hemorrhagic shock. Shock (2016) 465:519–26. doi: 10.1097/SHK.0000000000000650

  • CrossRef
  • Google Scholar

• 79

  Goering J Pope MR Fleming SD . Tlr2 regulates complement-mediated inflammation induced by blood loss during hemorrhage. Shock (2016) 451:33–9. doi: 10.1097/SHK.0000000000000477

  • CrossRef
  • Google Scholar

• 80

  Aziz M Brenner M Wang P . Extracellular cirp (Ecirp) and inflammation. J Leukoc Biol (2019) 1061:133–46. doi: 10.1002/JLB.3MIR1118-443R

  • CrossRef
  • Google Scholar

• 81

  Idrovo JP Jacob A Yang WL Wang Z Yen HT Nicastro J et al . A deficiency in cold-inducible rna-binding protein accelerates the inflammation phase and improves wound healing. Int J Mol Med (2016) 372:423–8. doi: 10.3892/ijmm.2016.2451

  • CrossRef
  • Google Scholar

• 82

  Ishikawa H Ma Z Barber GN . Sting regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature (2009) 4617265:788–92. doi: 10.1038/nature08476

  • CrossRef
  • Google Scholar

• 83

  Ishikawa H Barber GN . Sting is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature (2008) 4557213:674–8. doi: 10.1038/nature07317

  • CrossRef
  • Google Scholar

• 84

  Chen K Cagliani J Aziz M Tan C Brenner M Wang P . Extracellular cirp activates sting to exacerbate hemorrhagic shock. JCI Insight (2021) 614:e143715. doi: 10.1172/jci.insight.143715

  • CrossRef
  • Google Scholar

• 85

  Huang X Chen Y Chung CS Yuan Z Monaghan SF Wang F et al . Identification of B7-H1 as a novel mediator of the innate Immune/Proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J Immunol (Baltimore Md 1950) (2014) 1923:1091–9. doi: 10.4049/jimmunol.1302252

  • CrossRef
  • Google Scholar

• 86

  Tang L Bai J Chung CS Lomas-Neira J Chen Y Huang X et al . Active players in resolution of Shock/Sepsis induced indirect lung injury: Immunomodulatory effects of tregs and pd-1. J Leukoc Biol (2014) 965:809–20. doi: 10.1189/jlb.4MA1213-647RR

  • CrossRef
  • Google Scholar

• 87

  Monaghan SF Thakkar RK Tran ML Huang X Cioffi WG Ayala A et al . Programmed death 1 expression as a marker for immune and physiological dysfunction in the critically ill surgical patient. Shock (2012) 382:117–22. doi: 10.1097/SHK.0b013e31825de6a3

  • CrossRef
  • Google Scholar

• 88

  Lomas-Neira J Monaghan S Huang X Fallon E Chung C Ayala A . Novel role for pd-1:Pd-L1 as mediator of pulmonary vascular endothelial cell functions in pathogenesis of indirect Ards in mice. Front Immunol (2018) 9:3030. doi: 10.3389/fimmu.2018.03030

  • CrossRef
  • Google Scholar

• 89

  Battino M Giampieri F Pistollato F Sureda A de Oliveira MR Pittala V et al . Nrf2 as regulator of innate immunity: A molecular Swiss army knife! Biotechnol Adv (2018) 362:358–70. doi: 10.1016/j.biotechadv.2017.12.012

  • CrossRef
  • Google Scholar

• 90

  Borcherding DC Siefert ME Lin S Brewington J Sadek H Clancy JP et al . Clinically-approved cftr modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia. J Clin Invest (2019) 1298:3448–63. doi: 10.1172/JCI96273

  • CrossRef
  • Google Scholar

• 91

  Zhou YQ Mei W Tian XB Tian YK Liu DQ Ye DW . The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies. Pharmacol Ther (2021) 225:107846. doi: 10.1016/j.pharmthera.2021.107846

  • CrossRef
  • Google Scholar

• 92

  Zhao H Hao S Xu H Ma L Zhang Z Ni Y et al . Protective role of nuclear factor erythroid 2-related factor 2 in the hemorrhagic shock-induced inflammatory response. Int J Mol Med (2016) 374:1014–22. doi: 10.3892/ijmm.2016.2507

  • CrossRef
  • Google Scholar

• 93

  Leung CH Caldarone CA Guan R Wen XY Ailenberg M Kapus A et al . Nuclear factor (Erythroid-derived 2)-like 2 regulates the hepatoprotective effects of remote ischemic conditioning in hemorrhagic shock. Antioxid Redox Signal (2019) 3014:1760–73. doi: 10.1089/ars.2018.7541

  • CrossRef
  • Google Scholar

• 94

  Long Y Wang C Xia C Li X Fan C Zhao X et al . Recovery of Cd226-Tigit(+)Foxp3(+) and Cd226-Tigit-Foxp3(+) regulatory T cells contributes to clinical remission from active stage in ulcerative colitis patients. Immunol Lett (2020) 218:30–9. doi: 10.1016/j.imlet.2019.12.007

  • CrossRef
  • Google Scholar

• 95

  Lozano E Joller N Cao Y Kuchroo VK Hafler DA . The Cd226/Cd155 interaction regulates the proinflammatory (Th1/Th17)/Anti-inflammatory (Th2) balance in humans. J Immunol (Baltimore Md 1950) (2013) 1917:3673–80. doi: 10.4049/jimmunol.1300945

  • CrossRef
  • Google Scholar

• 96

  Zhou S Xie J Yu C Feng Z Cheng K Ma J et al . Cd226 deficiency promotes glutaminolysis and alleviates mitochondria damage in vascular endothelial cells under hemorrhagic shock. FASEB J Off Publ Fed Am Societies Exp Biol (2021) 3511:e21998. doi: 10.1096/fj.202101134R

  • CrossRef
  • Google Scholar

• 97

  Neudecker V Yuan X Bowser JL Eltzschig HK . Micrornas in mucosal inflammation. J Mol Med (2017) 959:935–49. doi: 10.1007/s00109-017-1568-7

  • CrossRef
  • Google Scholar

• 98

  Wu XQ Dai Y Yang Y Huang C Meng XM Wu BM et al . Emerging role of micrornas in regulating macrophage activation and polarization in immune response and inflammation. Immunology (2016) 1483:237–48. doi: 10.1111/imm.12608

  • CrossRef
  • Google Scholar

• 99

  Sheng X Yang Y Liu J Yu J Guo Q Guan W et al . Down-regulation of mir-18b-5p protects against splenic hemorrhagic shock by directly targeting hif-1α/Inos pathway. Immunobiology (2022) 2272:152188. doi: 10.1016/j.imbio.2022.152188

  • CrossRef
  • Google Scholar

• 100

  Messerer DAC Halbgebauer R Nilsson B Pavenstadt H Radermacher P Huber-Lang M . Immunopathophysiology of trauma-related acute kidney injury. Nat Rev Nephrol (2021) 172:91–111. doi: 10.1038/s41581-020-00344-9

  • CrossRef
  • Google Scholar

• 101

  Karasu E Nilsson B Köhl J Lambris J Huber-Lang M . Targeting complement pathways in polytrauma- and sepsis-induced multiple-organ dysfunction. Front Immunol (2019) 10:543. doi: 10.3389/fimmu.2019.00543

  • CrossRef
  • Google Scholar

• 102

  Cai C Gill R Eum HA Cao Z Loughran PA Darwiche S et al . Complement factor 3 deficiency attenuates hemorrhagic shock-related hepatic injury and systemic inflammatory response syndrome. Am J Physiol Regulatory Integr Comp Physiol (2010) 2995:R1175–82. doi: 10.1152/ajpregu.00282.2010

  • CrossRef
  • Google Scholar

• 103

  van Griensven M Ricklin D Denk S Halbgebauer R Braun C Schultze A et al . Protective effects of the complement inhibitor compstatin Cp40 in hemorrhagic shock. Shock (Augusta Ga) (2019) 511:78–87. doi: 10.1097/shk.0000000000001127

  • CrossRef
  • Google Scholar

• 104

  Chen D Song MQ Liu YJ Xue YK Cheng P Zheng H et al . Inhibition of complement C3 might rescue vascular hyporeactivity in a conscious hemorrhagic shock rat model. Microvascular Res (2016) 105:23–9. doi: 10.1016/j.mvr.2015.12.006

  • CrossRef
  • Google Scholar

• 105

  Dalle Lucca J Li Y Simovic M Pusateri A Falabella M Dubick M et al . Effects of C1 inhibitor on tissue damage in a porcine model of controlled hemorrhage. Shock (Augusta Ga) (2012) 381:82–91. doi: 10.1097/SHK.0b013e31825a3522

  • CrossRef
  • Google Scholar

• 106

  Hylton DJ Hoffman SM Van Rooijen N Tomlinson S Fleming SD . Macrophage-produced il-12p70 mediates hemorrhage-induced damage in a complement-dependent manner. Shock (2011) 352:134–40. doi: 10.1097/SHK.0b013e3181ed8ec9

  • CrossRef
  • Google Scholar

• 107

  Hylton DJ Phillips LM Hoffman SM Fleming SD . Hemorrhage-induced intestinal damage is complement-independent in helicobacter hepaticus-infected mice. Shock (2010) 345:467–74. doi: 10.1097/SHK.0b013e3181dc077e

  • CrossRef
  • Google Scholar

• 108

  Fleming SD Phillips LM Lambris JD Tsokos GC . Complement component C5a mediates hemorrhage-induced intestinal damage. J Surg Res (2008) 1502:196–203. doi: 10.1016/j.jss.2008.02.010

  • CrossRef
  • Google Scholar

• 109

  Huang Y Qiao F Atkinson C Holers VM Tomlinson S . A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in Ischemia/Reperfusion injury. J Immunol (Baltimore Md 1950) (2008) 18111:8068–76. doi: 10.4049/jimmunol.181.11.8068

  • CrossRef
  • Google Scholar

• 110

  Chu C Yang C Wang X Xie T Sun S Liu B et al . Early intravenous administration of tranexamic acid ameliorates intestinal barrier injury induced by neutrophil extracellular traps in a rat model of Trauma/Hemorrhagic shock. Surgery (2020) 1672:340–51. doi: 10.1016/j.surg.2019.10.009

  • CrossRef
  • Google Scholar

• 111

  Zhang F Yang W Brenner M Wang P . Attenuation of hemorrhage-associated lung injury by adjuvant treatment with C23, an oligopeptide derived from cold-inducible rna-binding protein. J Trauma acute Care Surg (2017) 834:690–7. doi: 10.1097/ta.0000000000001566

  • CrossRef
  • Google Scholar

• 112

  Fenizia C Galbiati S Vanetti C Vago R Clerici M Tacchetti C et al . Cyclosporine a inhibits viral infection and release as well as cytokine production in lung cells by three sars-Cov-2 variants. Microbiol Spectr (2022) 101:e0150421. doi: 10.1128/spectrum.01504-21

  • CrossRef
  • Google Scholar

• 113

  Kim K Shin J Lee J Jo Y Kim M Lee K et al . The effect of cyclosporine a in hemorrhagic shock model of rats. J Trauma acute Care Surg (2015) 782:370–7. doi: 10.1097/ta.0000000000000511

  • CrossRef
  • Google Scholar

• 114

  Gui Q Jiang Z Zhang L . Insights into the modulatory role of cyclosporine a and its research advances in acute inflammation. Int Immunopharmacol (2021) 93:107420. doi: 10.1016/j.intimp.2021.107420

  • CrossRef
  • Google Scholar

• 115

  Biesterveld B Wakam G Kemp M Williams A Shamshad A O'Connell R et al . Histone deacetylase 6 inhibition improves survival in a swine model of lethal hemorrhage, polytrauma, and bacteremia. J Trauma acute Care Surg (2020) 895:932–9. doi: 10.1097/ta.0000000000002677

  • CrossRef
  • Google Scholar

• 116

  Nikolian V Dennahy I Weykamp M Williams A Bhatti U Eidy H et al . Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock. J Trauma acute Care Surg (2019) 862:232–9. doi: 10.1097/ta.0000000000002119

  • CrossRef
  • Google Scholar

• 117

  Georgoff P Nikolian V Higgins G Chtraklin K Eidy H Ghandour M et al . Valproic acid induces prosurvival transcriptomic changes in swine subjected to traumatic injury and hemorrhagic shock. J Trauma Acute Care Surg (2018) 844:642–9. doi: 10.1097/ta.0000000000001763

  • CrossRef
  • Google Scholar

• 118

  Bambakidis T Dekker S Sillesen M Liu B Johnson C Jin G et al . Resuscitation with valproic acid alters inflammatory genes in a porcine model of combined traumatic brain injury and hemorrhagic shock. J Neurotrauma (2016) 3316:1514–21. doi: 10.1089/neu.2015.4163

  • CrossRef
  • Google Scholar

• 119

  Chang P Williams A Bhatti U Biesterveld B Liu B Nikolian V et al . Valproic acid and neural apoptosis, inflammation, and degeneration 30 days after traumatic brain injury, hemorrhagic shock, and polytrauma in a swine model. J Am Coll Surgeons (2019) 2283:265–75. doi: 10.1016/j.jamcollsurg.2018.12.026

  • CrossRef
  • Google Scholar

• 120

  Sailhamer E Li Y Smith E Shuja F Shults C Liu B et al . Acetylation: A novel method for modulation of the immune response following Trauma/Hemorrhage and inflammatory second hit in animals and humans. Surgery (2008) 1442:204–16. doi: 10.1016/j.surg.2008.03.034

  • CrossRef
  • Google Scholar

• 121

  Mazzola MA Raheja R Murugaiyan G Rajabi H Kumar D Pertel T et al . Identification of a novel mechanism of action of fingolimod (Fty720) on human effector T cell function through tcf-1 upregulation. J Neuroinflamm (2015) 12:245. doi: 10.1186/s12974-015-0460-z

  • CrossRef
  • Google Scholar

• 122

  Luessi F Kraus S Trinschek B Lerch S Ploen R Paterka M et al . Fty720 (Fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis. Multiple Sclerosis (Houndmills Basingstoke England) (2015) 2114:1811–22. doi: 10.1177/1352458515574895

  • CrossRef
  • Google Scholar

• 123

  Hawksworth J Graybill J Brown T Wallace S Davis T Tadaki D et al . Lymphocyte modulation with Fty720 improves hemorrhagic shock survival in swine. PloS One (2012) 74:e34224. doi: 10.1371/journal.pone.0034224

  • CrossRef
  • Google Scholar

• 124

  Bonitz J Son J Chandler B Tomaio J Qin Y Prescott L et al . A sphingosine-1 phosphate agonist (Fty720) limits Trauma/Hemorrhagic shock-induced multiple organ dysfunction syndrome. Shock (Augusta Ga) (2014) 425:448–55. doi: 10.1097/shk.0000000000000227

  • CrossRef
  • Google Scholar

• 125

  Xu D Horst K Wang W Luo P Shi Y Tschernig T et al . The influence of macrophage-activating lipopeptide 2 (Malp-2) on local and systemic inflammatory response in a murine two-hit model of hemorrhagic shock and subsequent sepsis. Inflammation (2021) 442:481–92. doi: 10.1007/s10753-020-01329-3

  • CrossRef
  • Google Scholar

• 126

  Liang W Greven J Qin K Fragoulis A Horst K Blasius F et al . Sulforaphane exerts beneficial immunomodulatory effects on liver tissue Via a Nrf2 pathway-related mechanism in a murine model of hemorrhagic shock and resuscitation. Front Immunol (2022) 13:822895. doi: 10.3389/fimmu.2022.822895

  • CrossRef
  • Google Scholar

• 127

  Liang W Greven J Fragoulis A Horst K Blasius F Wruck C et al . Sulforaphane-dependent up-regulation of Nrf2 activity alleviates both systemic inflammatory response and lung injury after hemorrhagic Shock/Resuscitation in mice. Shock (2022) 572:221–9. doi: 10.1097/SHK.0000000000001859

  • CrossRef
  • Google Scholar

• 128

  Guan Z Zhou L Zhang Y Zhang Y Chen H Shao F . Sulforaphane ameliorates the liver injury of traumatic hemorrhagic shock rats. J Surg Res (2021) 267:293–301. doi: 10.1016/j.jss.2021.05.004

  • CrossRef
  • Google Scholar

• 129

  Kulkarni SS Canto C . The molecular targets of resveratrol. Biochim Biophys Acta (2015) 18526:1114–23. doi: 10.1016/j.bbadis.2014.10.005

  • CrossRef
  • Google Scholar

• 130

  Ayub A Poulose N Raju R . Resveratrol improves survival and prolongs life following hemorrhagic shock. Mol Med (Cambridge Mass) (2015) 21:305–12. doi: 10.2119/molmed.2015.00013

  • CrossRef
  • Google Scholar

• 131

  Pradere JP Hernandez C Koppe C Friedman RA Luedde T Schwabe RF . Negative regulation of nf-kappab P65 activity by serine 536 phosphorylation. Sci Signaling (2016) 9442:ra85. doi: 10.1126/scisignal.aab2820

  • CrossRef
  • Google Scholar

• 132

  Rabb H Griffin MD McKay DB Swaminathan S Pickkers P Rosner MH et al . Inflammation in aki: Current understanding, key questions, and knowledge gaps. J Am Soc Nephrol (2016) 272:371–9. doi: 10.1681/ASN.2015030261

  • CrossRef
  • Google Scholar

• 133

  Sheng X Yang Y Liu J Yu J Guo Q Guan W et al . Ophiopogonin a alleviates hemorrhagic shock-induced renal injury Via induction of Nrf2 expression. Front Physiol (2020) 11:619740. doi: 10.3389/fphys.2020.619740

  • CrossRef
  • Google Scholar

• 134

  Luciani C Hager FT Cerovic V Lelouard H . Dendritic cell functions in the inductive and effector sites of intestinal immunity. Mucosal Immunol (2022) 151:40–50. doi: 10.1038/s41385-021-00448-w

  • CrossRef
  • Google Scholar

• 135

  Zhang Y Zhang J Xu T Wu W Huang F Yu W et al . Allicin ameliorates intraintestinal bacterial translocation after Trauma/Hemorrhagic shock in rats: The role of mesenteric lymph node dendritic cell. Surgery (2017) 1612:546–55. doi: 10.1016/j.surg.2016.08.029

  • CrossRef
  • Google Scholar

• 136

  Xu S Liao Y Wang Q Liu L Yang W . Current studies and potential future research directions on biological effects and related mechanisms of allicin. Crit Rev Food Sci Nutr (2022) 2049691:1–27. doi: 10.1080/10408398.2022.2049691

  • CrossRef
  • Google Scholar

• 137

  Slate JR Chriswell BO Briggs RE McGill JL . The effects of ursolic acid treatment on immunopathogenesis following mannheimia haemolytica infections. Front Veterinary Sci (2021) 8:782872. doi: 10.3389/fvets.2021.782872

  • CrossRef
  • Google Scholar

• 138

  Jung TY Pham TN Umeyama A Shoji N Hashimoto T Lee JJ et al . Ursolic acid isolated from uncaria rhynchophylla activates human dendritic cells via Tlr2 and/or Tlr4 and induces the production of ifn-gamma by Cd4+ naive T cells. Eur J Pharmacol (2010) 6432-3:297–303. doi: 10.1016/j.ejphar.2010.06.030

  • CrossRef
  • Google Scholar

• 139

  Hwang TL Shen HI Liu FC Tsai HI Wu YC Chang FR et al . Ursolic acid inhibits superoxide production in activated neutrophils and attenuates trauma-hemorrhage shock-induced organ injury in rats. PloS One (2014) 910:e111365. doi: 10.1371/journal.pone.0111365

  • CrossRef
  • Google Scholar

• 140

  Xiang M Yin L Li Y Xiao G Vodovotz Y Billiar TR et al . Hemorrhagic shock activates lung endothelial reduced nicotinamide adenine dinucleotide phosphate (Nadph) oxidase Via neutrophil nadph oxidase. Am J Respir Cell Mol Biol (2011) 443:333–40. doi: 10.1165/rcmb.2009-0408OC

  • CrossRef
  • Google Scholar

• 141

  Tsai YF Yu HP Chung PJ Leu YL Kuo LM Chen CY et al . Osthol attenuates neutrophilic oxidative stress and hemorrhagic shock-induced lung injury Via inhibition of phosphodiesterase 4. Free Radical Biol Med (2015) 89:387–400. doi: 10.1016/j.freeradbiomed.2015.08.008

  • CrossRef
  • Google Scholar

• 142

  Liu H Zhao Z Xing L Zhang L Niu C . Post-shock mesenteric lymph drainage ameliorates cellular immune function in rats following hemorrhagic shock. Inflammation (2015) 382:584–94. doi: 10.1007/s10753-014-9965-3

  • CrossRef
  • Google Scholar

• 143

  Morishita K Coimbra R Langness S Eliceiri BP Costantini TW . Neuroenteric axis modulates the balance of regulatory T cells and T-helper 17 cells in the mesenteric lymph node following Trauma/Hemorrhagic shock. Am J Physiol Gastrointestinal Liver Physiol (2015) 3093:G202–8. doi: 10.1152/ajpgi.00097.2015

  • CrossRef
  • Google Scholar

• 144

  Wu J Yin Y Qin M Li K Liu F Zhou X et al . Vagus nerve stimulation protects enterocyte glycocalyx after hemorrhagic shock Via the cholinergic anti-inflammatory pathway. Shock (2021) 565:832–9. doi: 10.1097/SHK.0000000000001791

  • CrossRef
  • Google Scholar

• 145

  Reys LG Ortiz-Pomales YT Lopez N Cheadle G de Oliveira PG Eliceiri B et al . Uncovering the neuroenteric-pulmonary axis: Vagal nerve stimulation prevents acute lung injury following hemorrhagic shock. Life Sci (2013) 9213:783–92. doi: 10.1016/j.lfs.2013.02.009

  • CrossRef
  • Google Scholar

• 146

  Li Y Du H Jiang L Wang C Yin M Zhang L et al . Stellate ganglion block improves the proliferation and function of splenic Cd4 + T cells through inhibition of posthemorrhagic shock mesenteric lymph-mediated autophagy. Inflammation (2021) 44:254353. doi: 10.1007/s10753-021-01523-x

  • CrossRef
  • Google Scholar

• 147

  Son J Chandler B Feketova E Qin Y Quackenbush E Deitch E . Oral pretreatment with recombinant human lactoferrin limits trauma-hemorrhagic shock-induced gut injury and the biological activity of mesenteric lymph. J Surg Res (2014) 1871:270–7. doi: 10.1016/j.jss.2013.10.026

  • CrossRef
  • Google Scholar

• 148

  Tian F Gao X Zhang L Wang X Wan X Jiang T et al . Effects of n-3 pufas on intestinal mucosa innate immunity and intestinal microbiota in mice after hemorrhagic shock resuscitation. Nutrients (2016) 810:609. doi: 10.3390/nu8100609

  • CrossRef
  • Google Scholar

• 149

  Xu DQ Gao C Niu W Li Y Wang YX Gao CJ et al . Sodium hydrosulfide alleviates lung inflammation and cell apoptosis following resuscitated hemorrhagic shock in rats. Acta Pharmacologica Sin (2013) 3412:1515–25. doi: 10.1038/aps.2013.96

  • CrossRef
  • Google Scholar

• 150

  Kojima M Gimenes-Junior J Chan T Eliceiri B Baird A Costantini T et al . Viaexosomes in postshock mesenteric lymph are key mediators of acute lung injury triggering the macrophage activation toll-like receptor 4. FASEB J Off Publ Fed Am Societies Exp Biol (2018) 321:97–110. doi: 10.1096/fj.201700488R

  • CrossRef
  • Google Scholar

• 151

  Cerovic V Houston SA Scott CL Aumeunier A Yrlid U Mowat AM et al . Intestinal Cd103- dendritic cells migrate in lymph and prime effector T cells. Mucosal Immunol (2013) 61:104–13. doi: 10.1038/mi.2012.53

  • CrossRef
  • Google Scholar

• 152

  Farache J Zigmond E Shakhar G Jung S . Contributions of dendritic cells and macrophages to intestinal homeostasis and immune defense. Immunol Cell Biol (2013) 913:232–9. doi: 10.1038/icb.2012.79

  • CrossRef
  • Google Scholar

• 153

  Dai H Sun T Liu Z Zhang J Zhou M . The imbalance between regulatory and il-17-Secreting Cd4(+)T cells in multiple-trauma rat. Injury (2013) 4411:1521–7. doi: 10.1016/j.injury.2013.03.015

  • CrossRef
  • Google Scholar

• 154

  Yagi M Morishita K Ueno A Nakamura H Akabori H Senda A et al . Electrical stimulation of the vagus nerve improves intestinal blood flow after trauma and hemorrhagic shock. Surgery (2020) 1673:638–45. doi: 10.1016/j.surg.2019.09.024

  • CrossRef
  • Google Scholar

• 155

  Morishita K Costantini TW Ueno A Bansal V Eliceiri B Coimbra R . A pharmacologic approach to vagal nerve stimulation prevents mesenteric lymph toxicity after hemorrhagic shock. J Trauma Acute Care Surg (2015) 781:52–8. doi: 10.1097/TA.0000000000000489

  • CrossRef
  • Google Scholar

• 156

  Morishita K Costantini TW Eliceiri B Bansal V Coimbra R . Vagal nerve stimulation modulates the dendritic cell profile in posthemorrhagic shock mesenteric lymph. J Trauma Acute Care Surg (2014) 763:610–7. doi: 10.1097/TA.0000000000000137

  • CrossRef
  • Google Scholar

• 157

  Luyer MD de Haan JJ Lubbers T Greve JW Buurman WA . Parasympathetic stimulation Via the vagus nerve prevents systemic organ dysfunction by abrogating gut injury and lymph toxicity in trauma and hemorrhagic shock. Shock (2013) 395:460–1. doi: 10.1097/SHK.0b013e31828def5a

  • CrossRef
  • Google Scholar

• 158

  Levy G Fishman JE Xu DZ Dong W Palange D Vida G et al . Vagal nerve stimulation modulates gut injury and lung permeability in trauma-hemorrhagic shock. J Trauma Acute Care Surg (2012) 732:338–42. doi: 10.1097/TA.0b013e31825debd3

  • CrossRef
  • Google Scholar

• 159

  Zhang J Lin XR Zhang YP Zhang LM Du HB Jiang LN et al . Blockade of stellate ganglion remediates hemorrhagic shock-induced intestinal barrier dysfunction. J Surg Res (2019) 244:69–76. doi: 10.1016/j.jss.2019.06.007

  • CrossRef
  • Google Scholar

• 160

  Ramalingam S Crawford J Chang A Manegold C Perez-Soler R Douillard JY et al . Talactoferrin Alfa versus placebo in patients with refractory advanced non-Small-Cell lung cancer (Fortis-m trial). Ann Oncol Off J Eur Soc Med Oncol (2013) 2411:2875–80. doi: 10.1093/annonc/mdt371

  • CrossRef
  • Google Scholar

• 161

  Riess JW Bhattacharya N Blenman KR Neal JW Hwang G Pultar P et al . Immune correlates of talactoferrin Alfa in biopsied tumor of Relapsed/Refractory metastatic non-small cell lung cancer patients. Immunopharmacol Immunotoxicol (2014) 362:182–6. doi: 10.3109/08923973.2013.864671

  • CrossRef
  • Google Scholar

• 162

  Madan RA Tsang KY Bilusic M Vergati M Poole DJ Jochems C et al . Effect of talactoferrin Alfa on the immune system in adults with non-small cell lung cancer. Oncologist (2013) 187:821–2. doi: 10.1634/theoncologist.2013-0199

  • CrossRef
  • Google Scholar

• 163

  Perez-Lopez A Behnsen J Nuccio SP Raffatellu M . Mucosal immunity to pathogenic intestinal bacteria. Nat Rev Immunol (2016) 163:135–48. doi: 10.1038/nri.2015.17

  • CrossRef
  • Google Scholar

• 164

  Ganster F Burban M de la Bourdonnaye M Fizanne L Douay O Loufrani L et al . Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats. Crit Care (2010) 145:R165. doi: 10.1186/cc9257

  • CrossRef
  • Google Scholar

• 165

  Mahmoud M Mason KP . Dexmedetomidine: Review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations. Br J Anaesthesia (2015) 1152:171–82. doi: 10.1093/bja/aev226

  • CrossRef
  • Google Scholar

• 166

  Jia Z Chen X Sun P Liu M Li X . The protective mechanism of dexmedetomidine on renal in hemorrhagic shock. Comput Math Methods Med (2022) 2022:6394544. doi: 10.1155/2022/6394544

  • CrossRef
  • Google Scholar

• 167

  Zhang Y Chen H Li YM Zheng SS Chen YG Li LJ et al . Thymosin Alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infect Dis (2008) 1985:723–30. doi: 10.1086/590500

  • CrossRef
  • Google Scholar

• 168

  Park KH Lee KH Kim H Hwang SO . The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci (2010) 251:128–34. doi: 10.3346/jkms.2010.25.1.128

  • CrossRef
  • Google Scholar

• 169

  Abdou H Morrison JJ Edwards J Patel N Lang E Richmond MJ et al . An estrogen (17alpha-ethinyl estradiol-3-Sulfate) reduces mortality in a swine model of multiple injuries and hemorrhagic shock. J Trauma Acute Care Surg (2022) 921:57–64. doi: 10.1097/TA.0000000000003434

  • CrossRef
  • Google Scholar

• 170

  Buleon M Cuny M Grellier J Charles PY Belliere J Casemayou A et al . A single dose of estrogen during hemorrhagic shock protects against kidney injury whereas estrogen restoration in ovariectomized mice is ineffective. Sci Rep (2020) 101:17240. doi: 10.1038/s41598-020-73974-5

  • CrossRef
  • Google Scholar

• 171

  Gupta D Tiwari S Sinha T Soni K Galwnkar S Kumar S et al . Estrogen as a safe therapeutic adjunct in reducing the inflammatory storm in trauma hemorrhagic shock patients. Shock (Augusta Ga) (2021) 56:514–21. doi: 10.1097/shk.0000000000001779

  • CrossRef
  • Google Scholar

• 172

  Guyette FX Sperry JL Peitzman AB Billiar TR Daley BJ Miller RS et al . Prehospital blood product and crystalloid resuscitation in the severely injured patient: A secondary analysis of the prehospital air medical plasma trial. Ann Surg (2021) 2732:358–64. doi: 10.1097/SLA.0000000000003324

  • CrossRef
  • Google Scholar

• 173

  Moore HB Moore EE Chapman MP McVaney K Bryskiewicz G Blechar R et al . Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: A randomised trial. Lancet (London England) (2018) 39210144:283–91. doi: 10.1016/S0140-67361831553-8

  • CrossRef
  • Google Scholar

• 174

  Bulger EM May S Kerby JD Emerson S Stiell IG Schreiber MA et al . Out-of-Hospital hypertonic resuscitation after traumatic hypovolemic shock: A randomized, placebo controlled trial. Ann Surg (2011) 2533:431–41. doi: 10.1097/SLA.0b013e3181fcdb22

  • CrossRef
  • Google Scholar

• 175

  Sloan EP Koenigsberg M Gens D Cipolle M Runge J Mallory MN et al . Diaspirin cross-linked hemoglobin (Dclhb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial. Jama (1999) 28219:1857–64. doi: 10.1001/jama.282.19.1857

  • CrossRef
  • Google Scholar